Startup · $18.9m raised
Adelaide, SA
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round GPN Vaccines raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator · Grant | - |
| Forepont Capital | Series B | - |
| Kern Capital | Series B | - |
| Mike Gregg | Series B | - |
Investors whose own portfolio pages list GPN Vaccines, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Shearwater Capital | its portfolio page ↗ |
Companies GPN Vaccines acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Mohammed Alsharifi | Founder | ausceleratesa.org, Business News Australia |
| Dr Tim Hurst | Founder | ausceleratesa.org, Business News Australia |
| James Paton | Founder | ausceleratesa.org, Business News Australia |
| Professor Tim Hirst | Chief Executive Officer | gpnvaccines.com, Brandon BioCatalyst, Brandon Capital, Techboard |
Stories naming GPN Vaccines. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
GPN Vaccines, an Adelaide biotech, has closed a A$18 million Series B1 that beat its 15 million target, co-led by Forepont Capital and Mike Gregg, with Kern Capital joining as a new investor.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org
Techboard announces the 2022 Australian Angel Awards winners, honouring Tim Hirst as Angel of the Year and Brisbane Angels for its Clipchamp exit, while recalling past raises and exits including Clarity Pharmaceuticals and Instaclustr.